CN116496414A - 一种检测马精液质量的联合检测抗体及其应用 - Google Patents
一种检测马精液质量的联合检测抗体及其应用 Download PDFInfo
- Publication number
- CN116496414A CN116496414A CN202310455192.4A CN202310455192A CN116496414A CN 116496414 A CN116496414 A CN 116496414A CN 202310455192 A CN202310455192 A CN 202310455192A CN 116496414 A CN116496414 A CN 116496414A
- Authority
- CN
- China
- Prior art keywords
- antibody
- seq
- functional fragment
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000283073 Equus caballus Species 0.000 title claims abstract description 43
- 238000001514 detection method Methods 0.000 title claims abstract description 33
- 210000000582 semen Anatomy 0.000 title claims abstract description 22
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 26
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 26
- 102000036639 antigens Human genes 0.000 claims abstract description 21
- 108091007433 antigens Proteins 0.000 claims abstract description 21
- 239000000427 antigen Substances 0.000 claims abstract description 20
- 241000700605 Viruses Species 0.000 claims abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 7
- 241000252868 H7N7 subtype Species 0.000 claims description 5
- 208000003857 African horse sickness Diseases 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 241000712461 unidentified influenza virus Species 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims 10
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 241000120516 African horse sickness virus Species 0.000 abstract description 35
- 230000003321 amplification Effects 0.000 abstract description 4
- 238000001962 electrophoresis Methods 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 4
- 238000003199 nucleic acid amplification method Methods 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 3
- 230000009545 invasion Effects 0.000 abstract description 3
- 210000002966 serum Anatomy 0.000 description 26
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 210000004408 hybridoma Anatomy 0.000 description 14
- 241000283086 Equidae Species 0.000 description 10
- 241000710803 Equine arteritis virus Species 0.000 description 9
- 108090000565 Capsid Proteins Proteins 0.000 description 7
- 102100023321 Ceruloplasmin Human genes 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 241000713730 Equine infectious anemia virus Species 0.000 description 6
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000037029 cross reaction Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 208000034657 Convalescence Diseases 0.000 description 2
- 241000712431 Influenza A virus Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 108091036078 conserved sequence Proteins 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000009027 insemination Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000134316 Culicoides <genus> Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000006854 communication Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000010460 detection of virus Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明提供一种检测马精液质量的联合检测抗体及其应用,同时本发明提供一种嵌合抗原表位融合蛋白。本发明所述的千合抗原表位融合蛋白及其单克隆抗体,能够实现快速、准确的对AHSV和EIV进行检测。经过交叉实验发现,本发明提供的抗体和检测方法可用于对马精液的快速检测,同时完成对AHSV、EIV的检测,特异性高,操作简便,不需要进行PCR后处理或电泳检测,克服了传统PCR技术存在的易污染及假阳性问题,可避免非特异性扩增,适合大批量样品的检测,有效的防范病毒入侵风险。
Description
技术领域
本发明涉及生物技术领域,更具体地,本发明涉及一种检测马精液质量的联合检测抗体及其应用,所述应用为在马精液的病毒检测防疫中的应用。
背景技术
我国是养马业大国,马匹数量居世界第二位。作为一种主要的大家畜,马曾经与人类生产生活息息相关,机械工业兴起后,马的役用价值弱化,逐渐淡出人们生活。近些年,随着我国人民生活水平的提高,以产品、文化休闲为主的现代马业在我国悄然兴起,现代马业的发展迫切需要采用人工授精的方式进行马匹改良,精液的体外保存(低温及冷冻保存)是目前马匹人工授精过程中的技术核心。但是马精液的保藏过程中最关键的一环就是对马精液的质量检测和保证。
非洲马瘟(African horse sickness,AHS)是由非洲马瘟病毒(African horsesickness virus,AHSV)引起的马属动物的一种急性传染病,通过库蠓等吸血昆虫叮咬传播,主要症状为发热、皮下水肿和病毒血症,马属动物中马最易感,病死率可高达95%,骡驴次之。这种传染病被世界动物卫生组织(WOAH)列为法定报告动物疫病,也是《一、二、三类动物疫病病种名录》和《中华人民共和国进境动物检疫疫病名录》中唯一的马属动物一类疫病。虽然现在国内没有发现,但周边国家已经广泛爆发,需要对其进行防范。
而马的流行性感冒是由属于A型流感病毒的马流感病毒(equine influenzavirus,EIV)引起马属动物的一种急性、高度接触性传染病。以发热、咳嗽、流浆液性鼻液为特征。OIE将其列为B类疫病,主要是H7N7和H3N8两个亚型。患马是主要传染源,康复马和隐性感染马在一定时间内也能带毒排毒。本病主要经呼吸道和消化道感染。康复公马精液中长期存在病毒,因此也可通过交配而传染。
现有技术中对上述精液中病毒的检测还都停留在利用病毒培养镜检、PCR或者RT-PCR的阶段,这种方法虽然检测的精度高,可以分辨具体的病毒分型,但是往往需要复杂的操作和昂贵的仪器,而且检测速度一般比较慢,都需要几个小时甚至几天的时间,在农场检测,对外交流过程中往往满足不了快速、准确的要求。这是因为在实际生产中,一般并不要求获知感染病毒的具体血清型或者基因型,而是对整体实施一票否决。为了解决上述实际生产需要及其现有技术中的缺点,研制具有自主知识产权的快速检测方法,我们研究团队从2012年至今开展了系列研究发明了一种检测马精液质量的联合检测抗体及其应用,在此基础上提出本申请的技术方案。
发明内容
为了解决上述技术问题,本发明的目的是:
提供一种经过优化改造的嵌合抗原表位融合蛋白,所述融合蛋白中含有AHSV的VP2(外衣壳蛋白)、VP7(内衣壳蛋白)、H7N7亚型的M基因、H3H8亚型的HA2基因的抗原表位;
进一步的,对上述抗原表位融合蛋白进行结构优化,最终确认嵌合抗原表位融合蛋白的氨基酸序列如SEQ ID NO.1所示。
QHMDSPDLPYNVQAMNDIVRSSGSLESAPGAPGTGSGSPLRIFCDPQGSSGSLWYTSLDRSLDTVPGSGSVDGVNVAAGDVVAWNSGSGSGQQSGRYYVPQGRTRGGYINSNIAEVCMDAGSSYPTLNVTMPNNKNFGSFSEVEGRIQDLEKYVEDGGGGSGGGGSYYMNNTEPLCDAQGFAPFSICVSECITPNGSISNDKPFQNVNKVTYGKCPKYIRQNTLKLATGMRNVYQARFESVAWSATACHDGKKWMTIGVTGPDNQATAIVNYGGIPVDIGGSGGSECICRDNWTGTNRPILVISSDLSYRVGYLCAGIPTDTPRGEDSQFTGSC AGFIENGWEGMVDGWYGFRYQNSEGTGQ(SEQ IDNO.1)。
进一步的,本发明证实了上述融合蛋白可以与AHSV抗体和EIV抗体都发生特异性反应,而与EAV和EIAV都没有交叉反应,保留了针对AHSV和EIV的特异性抗原活性。
进一步的,本发明提供了针对上述融合蛋白的单克隆抗体,所述抗体对AHSV、EIV呈阳性而对EAV为阴性,证实了上述抗体可以有效识别AHSV、EIV而与无免疫交叉反应,具有较好的免疫原性。
进一步的,本发明提供了上述单克隆抗体的重链和轻链的氨基酸序列,分别如SEQID NO:3和SEQ ID NO:11所示。
进一步的,本发明提供一种上述融合蛋白和单克隆抗体在马精液检测中的应用,所述应用为在马精液保藏前对马精液进行病原排除性检测,所述检测为非疾病的诊断和治疗目的。
有益效果
本发明提供一种含有AHSV的VP2(外衣壳蛋白)、VP7(内衣壳蛋白)、H7N7亚型的M基因、H3H8亚型的HA2基因的抗原表位的融合蛋白,所述融合蛋白具有较强的抗原特异性,仅与AHSV和EIV发生抗原抗体反应,与其他的常见马传染性病毒并没有相应的亲和反应。
本发明提供了一种针对上述抗原融合蛋白的单克隆抗体,能够实现快速、准确的对AHSV和EIV进行检测。经过交叉实验发现,本发明提供的抗体和检测方法可用于对马精液的快速检测,同时完成对AHSV、EIV的检测,特异性高,操作简便,不需要进行PCR后处理或电泳检测,克服了传统PCR技术存在的易污染及假阳性问题,可避免非特异性扩增,适合大批量样品的检测,有效的防范病毒入侵风险。
附图说明
图1为经过优化改造的嵌合抗原表位融合蛋白的3-D结构预测图;
图2为融合蛋白与各病毒血清反应示意图,其中M为Marker,1-6分别为抗AHSV的VP2多克隆兔血清、抗AHSV的VP7多克隆兔血清、抗EIV H7N7 M蛋白小鼠血清、抗EIV H3H8HA2蛋白小鼠血清、抗马动脉炎病毒(EAV)的多克隆小鼠血清、抗马传染性贫血病毒(EIAV)的多克隆小鼠血清(1:4000);
图3为马精子的正常图片(A)和非正常图片(B)。
具体实施方式
除非另有说明,否则本文中使用的科学和技术名词具有本领域技术人员所通常理解的含义。并且,本文中所用的细胞培养、分子遗传学、核酸化学、免疫学实验室操作步骤均为相应领域内广泛使用的常规步骤。同时,为了更好地理解本发明,下面提供相关术语的定义和解释。
为了使本领域的技术人员更好地理解本发明的技术方案,下面结合具体实施例对本发明作进一步的详细说明。
实施例1嵌合抗原表位的优化分析
根据现有技术中公开的内容,根据NCBI登录的病毒序列,针对非洲马瘟病毒的9个血清型、A型流感病毒H7N7和H3N8两个亚型进行基因序列分析,通过DNAstar软件进行序列比对,找出针对上述病原基因序列的特异性保守序列。运用Integrated DNA Technologies(https://sg.idtdna.com/site)中的PrimerQuest Tool工具,针对上述病毒基因的特异性保守序列,选择AHSV的VP2(外衣壳蛋白)、VP7(内衣壳蛋白)、H7N7亚型的M基因、H3H8亚型的HA2基因的表位,进行优化,根据其预测的高级结构利用柔性和刚性linker进行表位人工融合连接,尽量暴露各个病毒的表位信息,最终确认嵌合抗原表位融合蛋白的氨基酸序列如SEQ ID NO.1所示。将获得的抗原表位融合蛋白交由华大基因(北京)进行生物合成、融合表达和蛋白纯化。
QHMDSPDLPYNVQAMNDIVRSSGSLESAPGAPGTGSGSPLRIFCDPQGSSGSLWYTSLDRSLDTVPGSGSVDGVNVAAGDVVAWNSGSGSGQQSGRYYVPQGRTRGGYINSNIAEVCMDAGSSYPTLNVTMPNNKNFGSFSEVEGRIQDLEKYVEDGGGGSGGGGSYYMNNTEPLCDAQGFAPFSICVSECITPNGSISNDKPFQNVNKVTYGKCPKYIRQNTLKLATGMRNVYQARFESVAWSATACHDGKKWMTIGVTGPDNQATAIVNYGGIPVDIGGSGGSECICRDNWTGTNRPILVISSDLSYRVGYLCAGIPTDTPRGEDSQFTGSC AGFIENGWEGMVDGWYGFRYQNSEGTGQ
实施例2嵌合抗原表位性质鉴定
用10%SDS-PAGE凝胶对纯化后的嵌合蛋白样品进行电泳,先于75伏电泳25min,然后于160伏电泳50min。电泳完成后,将凝胶上的蛋白通过转膜的形式转移至硝酸纤维素(NC)膜上,转膜参数为40V、1h。取出转有蛋白的NC膜,用含5%脱脂奶粉的封闭液在常温下封闭1h。用PBST洗涤封闭完的NC膜一次。加一抗后于4℃过夜孵育,一抗分别为抗AHSV的VP2多克隆兔血清(1:5000)、抗AHSV的VP7多克隆兔血清(1:5000)、抗EIV H7N7 M蛋白小鼠血清(1:2000)、抗EIV H3H8 HA2蛋白小鼠血清(1:1000)、抗马动脉炎病毒(EAV)的多克隆小鼠血清(1:4000)、抗马传染性贫血病毒(EIAV)的多克隆小鼠血清(1:4000)。次日,用PBST洗膜3次,10min/次,然后孵育辣根过氧化物酶标记的(HRP-labeled)抗兔(1:10000)或抗鼠二抗(1:5000),于室温孵育2h。用PBST洗膜3次,20min/次,最后用增强化学发光法(ECL)进行显色。结果显示,实施例1获得的融合蛋白可以与AHSV抗体和EIV抗体都发生特异性反应,而与EAV和EIAV都没有交叉反应,结果证实获得的蛋白保留了针对AHSV和EIV的特异性抗原活性。
实施例3单克隆抗体的筛选和制备
选用6周龄雌性Balb/C小鼠(河南大学生命科学院实验动物中心提供),采用标准的体内免疫方式和PEG融合方法获得单克隆抗体,详细方法参见Ed Harlow等人,“Antibodies ALaboratory Manual”,Cold Spring Harbor Laboratory 1988.简要过程如下:
小鼠免疫:将纯化后的嵌合抗原表位融合蛋白稀释到1mg/ml,与弗氏完全佐剂(CFA)等体积混合乳化,经四肢肌肉多点注射,每只每次注射300μl。初免后21天,以弗氏不完全佐剂乳化的嵌合抗原表位融合蛋白皮下接种再次免疫。二免10天后,通过尾静脉采血,制备血清,以间接ELISA进行抗体水平检测。ELISA结果显示,5只免疫小鼠血清中的抗体达到1:32000稀释倍以上。二免后21天,选择2只嵌合抗原表位融合蛋白抗体水平高的小鼠,通过尾静脉注射嵌合抗原表位融合蛋白加强免疫。
细胞融合:取血清效价最高的小鼠脾脏细胞与小鼠骨髓瘤细胞相融合,先将脾脏研磨得到脾细胞悬液,然后与细胞数低五倍的处于对数生长期的SP2/0小鼠骨髓瘤细胞混合,经PEG1500作用1min,将两种细胞融合在一起,然后把400ml融合细胞液分装到20块96孔板中培养。融合培养基为含HAT和20%FBS的RPMI1640完全筛选培养基。通过间接ELISA筛选抗原特异性克隆,经3次克隆化后,同一杂交瘤细胞株在96孔板上检测孔阳性率达到100%,将杂交瘤细胞扩大培养保存,得到稳定的单克隆抗体细胞株。
杂交瘤的筛选:在酶标板预先包被20ng/孔嵌合融合蛋白。1:20稀释的灭活阳性AHSV马血清和阴性马血清(或灭活阳性EIV马血清和阴性马血清)以100μL/孔分别加入不同孔中,一列阳性血清间隔一列阴性血清,37℃孵育1h。经PBST洗涤后,加入杂交瘤细胞上清,37℃孵育1h。经PBST洗涤后,加入hrp标记的羊抗鼠抗体,37℃孵育1h。PBST洗涤后,加入TMD室温作用15min,2M的浓硫酸终止反应,酶标仪测定OD450值。竞争ELISA检测结果显示:一株杂交瘤细胞4-9的阴性AHSV马血清/阳性AHSV马血清(N/P)的值为3.59,阴性EIV马血清/阳性EIV马血清(N/P)的值为3.11,显示出该株杂交瘤细胞分泌单抗与马血清中的AHSV抗体和EIV抗体都有较好的竞争抑制作用。
杂交瘤的培养:稳定的杂交瘤单克隆抗体细胞株先在二氧化碳培养箱中扩增培养,经96孔板转移至24孔板,再转移至100ml细胞瓶内扩增培养。然后收集细胞瓶内的细胞注射到小鼠腹腔内,7-10天后从小鼠腹腔中吸取腹水。
单克隆抗体的纯化:腹水先用50%的硫铵沉淀处理,然后对20mMPB,pH7.4透析,之后用DEAE柱在HPLC下纯化,得到纯化后的单克隆抗体,经SDS-PAGE鉴定纯化后的单克隆抗体纯度。
实施例4抗体性质检测
4.1不同来源的马血清对4-9株单克隆抗体抑制效果检测
将从不同马场和畜牧兽医站收集到10份经PCR检测阳性AHSV马精液、8份阳性EIV马精液和24份AHSV阴性且EIV阴性马精液均作1:20稀释,应用上述竞争ELISA方法进行检测,结果显示,阳性样品与阴性样品OD值存在极显著差异,AHSV的平均OD值N/P为4.14,EIV的平均OD值N/P为3.89。这表明所测不同阳性精液对4-9株单抗均具有良好的抑制作用(图3)。
4.2 4-9株单克隆抗体对抗原蛋白的识别
将AHSV的VP2(外衣壳蛋白)、VP7(内衣壳蛋白)、H7N7亚型的M基因、H3H8亚型的HA2基因蛋白进行原核表达纯化后,进行SDS-PAGE,随后转膜,以4-9株单抗作为一抗,进行western blotting分析。结果显示,4-9株单抗可以识别上述蛋白。
4-9株单抗与AHSV、EIV和EAV做ELISA实验,结果显示对AHSV、EIV呈阳性而对EAV为阴性,说明上述抗体可以有效识别AHSV、EIV而与无免疫交叉反应,具有较好的免疫原性。4.3 4-9株单克隆杂交瘤的稳定性
将4-9株单克隆杂交瘤细胞株连续传代10代,计数第10代细胞数量,取150个细胞分种至96孔板。培养10天后,随机取22孔细胞上清,进行间接ELISA检测。各孔上清OD450值如表,所有孔均为阳性。这表明,4-9株杂交瘤细胞能稳定分泌相应的抗体。
4.4 2-3株单克隆抗体亚型鉴定
应用proteintech公司的小鼠单克隆抗体亚型鉴定试剂盒分析4-9株单克隆抗体的亚型。按照试剂盒说明书,将4-9株培养上清进行鉴定。试剂盒测定的值(表1)显示,该株单抗重链为IgG2b亚型,轻链为Kappa亚型。
表1.4-9株单抗亚型鉴定
45 4-9株单克隆抗体亚型鉴定
培养于6孔板中的4-9株杂交瘤细胞,移出上清后,每孔加入1mL Trizol裂解细胞,将裂解样品收集于1.5mL离心管,暂存于-80℃,将样品提交生物技术公司进行小鼠杂交瘤细胞单克隆抗体可变区测序。测序结果如下:
VH:
EVQSCALVLVNPGGESGGDSLKLASGSYFTFSGMSWWFRQTPEDKRLVATIYSSDTGYYPD SVKGTLYLQRFTISRDNAKNMTAMYSSLRSEDYCARFMDYGDFANYWGQTVSGTSVS(SE Q ID NO:2);
FR1:EVQSCALVLVNPGGESGGDSLKLAS(SEQ ID NO:3);
CDR1:GSYFTFSG(SEQ ID NO:4);
FR2:MSWWFRQTPEDKRLVAT(SEQ ID NO:5);
CDR2:IYSSDTG(SEQ ID NO:6);
FR3:YYPDSVKGTLYLQRFTISRDNAKNMTAMYSSLRSEDYC(SEQ ID NO:7);
CDR3:ARFMDYGDFANY(SEQ ID NO:8);
FR4:WGQTVSGTSVS(SEQ ID NO:9)。
VL:
DVVMTQTPVSLPLSLGDQSISCRASSQSHSNLVGTDYLHWYLQKPPKLGQSLIYLTSNRFSR FSGVPDGSGSGTDFTKISRLGLVEAEDVYFCSVPQSSHTWFGGRLGTEIK(SEQ ID NO:10)FR1:DVVMTQTPVSLPLSLGDQSISCRASS(SEQ ID NO:11)
CDR1:QSHSNLVGTDY(SEQ ID NO:12)
FR2:LHWYLQKPPKLGQSLIY(SEQ ID NO:13)
CDR2:LTS(SEQ ID NO:14)
FR3:NRFSRFSGVPDGSGSGTDFTKISRLGLVEAEDVYFC(SEQ ID NO:15)
CDR3:SVPQSSHTW(SEQ ID NO:16)
FR4:FGGRLGTEIK(SEQ ID NO:17)。
通过上述实施实例,本发明制备了一株可以快速识别AHSV、EIV的克隆抗体杂交瘤细胞株4-9,并进一步鉴定了该株单抗的具体序列。该株单抗可用于对马精液的快速检测,同时完成对AHSV、EIV的检测,特异性高,操作简便,不需要进行PCR后处理或电泳检测,克服了传统PCR技术存在的易污染及假阳性问题,可避免非特异性扩增,适合大批量样品的检测,有效的防范病毒入侵风险。
前述内容出于解释目的描述了一些示例性实施方案。尽管前面的讨论已经给出了具体的实施方案,但是本领域技术人员将认识到,可以在形式和细节上做出改变,而不脱离本发明的更广泛的精神和范围。因此,说明书和附图应当以说明性的而不是限制性的意义考虑。因此,该详细描述不应以限制性意义理解,并且本发明的范围仅由所包括的权利要求书以及这些权利要求书所享有的等同方案的全部范围来限定。
Claims (10)
1.一种含有非洲马瘟的VP2、VP7、马流感病毒H7N7亚型的M基因、H3H8亚型的HA2基因的抗原表位的嵌合抗原表位融合蛋白,其特征在于所述嵌合抗原表位融合蛋白的氨基酸序列如SEQ ID NO.1所示。
2.一株可以同时识别非洲马瘟和马流感病毒的单克隆抗体或其功能性片段,其特征在于,所述抗体或其功能性片段具有重链可变区和轻链可变区,其中,所述重链可变区的互补决定区HCDR1、HCDR2和HCDR3的氨基酸序列和所述轻链可变区的互补决定区LCDR1、LCDR2和LCDR3的氨基酸序列为:
HCDR1如SEQ ID NO.4所示,HCDR2如SEQ ID NO.6所示,HCDR3如SEQ ID NO.8所示;LCDR1如SEQ ID NO.12所示,LCDR2如SEQ ID NO.14所示,LCDR3如SEQ ID NO.16所示。
3.根据权利要求2所述的抗体或其功能性片段,其特征在于,所述重链可变区和所述轻链可变区的氨基酸序列为:所述重链可变区如SEQ ID NO.2所示,所述轻链可变区如SEQ IDNO.10所示。
4.根据权利要求3所述的抗体或其功能性片段,其特征在于,所述抗体的轻链恒定区为κ型轻链恒定区或λ型轻链恒定区。
5.根据权利要求3所述的抗体或其功能性片段,其特征在于,所述抗体的重链恒定区为IgA、IgD、IgE、IgG或IgM抗体的重链恒定区。
6.根据权利要求2-5任一项所述的抗体或其功能性片段,其特征在于,所述功能性片段为Fab、Fab’、F(ab’)2、Fv或ScFv片段。
7.一种分离的核酸分子,其特征在于,其编码如权利要求1所述的嵌合抗原表位融合蛋白,或权利要求2-6中任一项所述的抗体或其功能性片段。
8.含有权利要求7所述的核酸分子的重组载体。
9.含有权利要求8所述的重组载体的重组细胞。
10.如权利要求1所述的嵌合抗原表位融合蛋白、权利要求2-6中任一项所述的抗体或其功能性片段、如权利要求7所述的核酸分子、如权利要求8所述的重组载体或权利要求9所述的重组细胞在制备马精液的病毒检测防疫药物中的应用,所述应用为非疾病的诊断和治疗用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310455192.4A CN116496414A (zh) | 2023-04-25 | 2023-04-25 | 一种检测马精液质量的联合检测抗体及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310455192.4A CN116496414A (zh) | 2023-04-25 | 2023-04-25 | 一种检测马精液质量的联合检测抗体及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116496414A true CN116496414A (zh) | 2023-07-28 |
Family
ID=87325959
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310455192.4A Pending CN116496414A (zh) | 2023-04-25 | 2023-04-25 | 一种检测马精液质量的联合检测抗体及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116496414A (zh) |
-
2023
- 2023-04-25 CN CN202310455192.4A patent/CN116496414A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN116836270B (zh) | 一种抗蓝舌病毒vp7蛋白的单克隆抗体及制备方法与用途 | |
CN112812178B (zh) | PCV3 Cap蛋白抗原表位肽、抗PCV3 Cap蛋白的单克隆抗体及其制备方法和应用 | |
CN114236128B (zh) | 一种检测猪急性腹泻综合征冠状病毒n蛋白抗体的阻断elisa试剂盒 | |
CN114088941B (zh) | 一种检测猪急性腹泻综合征冠状病毒的双抗体夹心elisa试剂盒 | |
CN115724952A (zh) | 一种靶向甲型流感病毒保守线性b细胞表位的广谱单克隆抗体及其应用 | |
CN109206509A (zh) | 与伪狂犬病病毒gD蛋白结合的单克隆抗体及其应用 | |
CN116769021B (zh) | 一种针对非洲马瘟病毒vp7蛋白的单克隆抗体及用途 | |
Balcioğlu et al. | SARS-CoV-2 neutralizing antibody development strategies | |
CN117783521A (zh) | 检测非洲猪瘟病毒p30蛋白抗体的竞争ELISA试剂盒 | |
CN109942702B (zh) | 一种人鼠嵌合抗HEV全分子IgG及其应用 | |
CN116217716A (zh) | 一种识别柯萨奇病毒a2、a4和a5的单克隆抗体及其应用 | |
CN116496414A (zh) | 一种检测马精液质量的联合检测抗体及其应用 | |
CN107619435B (zh) | 一种猪瘟病毒e2蛋白的抗原表位、抗体的制备及应用 | |
CN118108837B (zh) | 口蹄疫病毒Asia1型中和性猪源单克隆抗体及其应用 | |
CN116640189B (zh) | 一种病原微生物快速检测试剂盒及其应用 | |
CN116444653B (zh) | 一株阻断性非洲猪瘟病毒单克隆抗体杂交瘤细胞株的制备与应用 | |
CN116874594B (zh) | 新型冠状病毒突变株xbb.1.5特异性抗体及其应用 | |
CN118005778A (zh) | 一株阻断性非洲猪瘟病毒p30蛋白单克隆抗体杂交瘤细胞株的制备与应用 | |
CN115819568B (zh) | 一种肠道病毒a71单克隆抗体及应用 | |
CN107163108A (zh) | 一种伪狂犬病病毒gE蛋白的抗原表位、抗体的制备及应用 | |
CN117050194B (zh) | 一种马传染性贫血病的抗体及其在精液检测中的应用 | |
CN116284360A (zh) | 识别cv-a4 vp1蛋白n末端的单克隆抗体及其应用 | |
CN118620042A (zh) | SARS-CoV-2冠状病毒囊膜表面S蛋白抗原表位及其单克隆抗体的制备筛选方法和应用 | |
CN117659173A (zh) | 抗PRV gC蛋白单克隆抗体、其制备方法及应用 | |
CN117209596A (zh) | 抗非洲猪瘟病毒p72蛋白中和活性单克隆抗体2c9及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |